Key Takeaways
- A CBD-enriched cannabis extract given via the oral mucosa over two weeks modestly reduced cold hyperalgesia in a rat model of chronic neuropathic pain.
- The study suggests that cannabis-based treatments may work partly by influencing immune cells involved in nerve pain signaling.
- Results are preliminary and animal-based — human trials are needed before any clinical conclusions can be drawn.
A new animal study suggests that a cannabidiol-enriched cannabis extract, delivered directly through the lining of the mouth, can partially reduce cold hypersensitivity in rats experiencing chronic neuropathic pain. The effect was described as moderate — not a complete reversal of pain sensitivity, but a meaningful reduction in one of nerve pain's most debilitating features.
After two weeks of oromucosal CBD-enriched extract, rats with neuropathic pain showed a moderate reduction in cold hyperalgesia — an abnormal, exaggerated pain response to cold temperatures.
Cold hyperalgesia is a hallmark of nerve pain and one of the symptoms most resistant to standard treatments.
Neuropathic pain — caused by damage or dysfunction in the nervous system itself — affects an estimated 7 to 10 percent of the general population and remains notoriously difficult to treat. Think of it less like a bruise that heals and more like a fire alarm that never shuts off, even when no emergency is present. Standard analgesics, such as common anti-inflammatory drugs, offer little relief for this type of pain, which is why researchers are actively exploring how the body's endocannabinoid system could be targeted instead.
The research team focused specifically on oromucosal administration — delivering the extract through the mucous membranes inside the mouth — which may allow for more consistent absorption compared to standard oral ingestion. The study also examined the relationship between CBD-enriched extracts and the immune cells that play a role in sustaining nerve pain, both resident immune cells at the injury site and those that travel in from the bloodstream. Exactly how cannabinoids alter these immune dynamics, however, remains an open question that this study highlights rather than resolves.
The preclinical nature of the findings is a significant caveat — what works in a rat model does not always translate to humans. Still, the study adds to a growing body of research positioning CBD-rich cannabis formulations as candidates for neuropathic pain management, and underscores a need for controlled human trials that can test both efficacy and immune-related mechanisms in clinical populations.
Oromucosal Administration of a Cannabidiol-Enriched Cannabis sp. Extract for 2 Weeks Moderately Reduces Cold Hyperalgesia in Rats With Neuropathic Pain.
Medical Disclaimer: The information provided on ChronicRelief.org is intended for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.